TTFields科研社区

致力于肿瘤治疗电场的应用基础研究

用户工具

站点工具

您的足迹: • aboutus
clinicaltrial

差别

这里会显示出您选择的修订版和当前版本之间的差别。

到此差别页面的链接

两侧同时换到之前的修订记录 前一修订版
后一修订版 		前一修订版
clinicaltrial [2021/04/05 11:06]
admin 		clinicaltrial [2021/04/16 13:18] (当前版本)
admin
行 2: 行 2:
  
 ---- ----
-TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine, The Franciszek Lukaszczyk Oncology CenterBydgoszcz, Poland.   Detailed Description:Almost all GBM patients experience recurrent disease. Stereotactic radiosurgery (SRS),at recurrence, has limitations due to the invasive nature of glioblastoma. TTFields may decrease the tumor aggressiveness outside the target area potentially by multiple pathways, including immunogenic cell death and DNA repair inhibition sensitizing to radiation. We hypothesize that combined SRS and TTFields will be complementary, improving outcomes with minimal toxicity.In this open-label, phase II trial 40 participants with recurrence will be treated with SRS and TTFields, starting in 2020. Recurrence will be defined on FET-PET or MRI using RANO criteria.All patients will begin treatment within 14 days from baseline imaging evaluation and at maximum 42 days from screening.The attempt to obtain the Methyl-guanine methyl-transferase (MGMT) gene promoter methylation and IDH1 and IDH2 mutation from primary tumor are made during the study whenever not defined before entering to the study.TTFields treatment will be initiated as in clinical routine at patients home. Admission to hospital will not be necessary.SRS must be delivered within 7 days of TTFields start. A 5-day SRS regimen is allowed. TTFields should be interrupted only during SRS. The sample size of the study was calculated for the comparison of survival against a historical control.Overall survival will be stratified by volume, PET-based treatment, SVZ invasion, MGMT methylation status, time to first progression, and TTFields compliance. 【复发性胶质母细胞瘤+/-18F氟乙基甲状腺素的治疗与放射外科，波兰弗朗西斯泽克卢卡斯茨克肿瘤中心。详细数据元素描述：几乎所有GBM患者经历复发性疾病。由于胶质母细胞瘤的侵袭性，立体定向放射外科（SRS）在复发时具有局限性。TTFields可能通过多种途径降低肿瘤在靶区外的侵袭性，包括免疫原性细胞死亡和对辐射敏感的DNA修复抑制。我们假设SRS和TTFields的结合将是互补的，以最小的代价改善结果，从2020年开始。40名复发患者将接受SRS和TTFields治疗。使用RANO在FET-PET或MRI上确定复发标准。全部患者将在基线影像学评估后14天内开始治疗，最多42天开始治疗筛选本研究尝试从原发性肿瘤中获得甲基鸟嘌呤甲基转移酶（MGMT）基因启动子甲基化和IDH1、IDH2突变在进入研究.TTFields治疗将在患者家中按照临床常规开始。不允许入院必要的SRS必须在开工后7天内交货。一个5天的SRS方案是允许的。TTFields只能在SRS期间中断。研究样本量的计算是为了将生存率与历史数据进行比较总体控制生存率将根据容积、PET治疗、SVZ侵袭、MGMT甲基化状态、首次进展时间和TTF依从性进行分层。】+TTFields临床试验列表，2021-4-5更新 
 + 
 +---- 
 + 
 +Study List: 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 1: 
 + 
 + NCT Number:          NCT04671459 
 + 
 + Title:            TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine 
 + 
 + Acronym:           TaRRGET 
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma Multiforme|Recurrent Glioblastoma 
 + 
 + Interventions:        Combination Product: TTFields and SRS 
 + 
 + Outcome Measures:       1-year survival rate|Radiation necrosis range|Progression free survival (PFS)|Steroid needs until treatment failure|Patterns of failure|Objective response rates 
 + 
 + Sponsor/Collaborators:    Prof. Franciszek Lukaszczyk Memorial Oncology Center|NovoCure GmbH 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          40 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          KB 2020 
 + 
 + Start Date:          December 26, 2020 
 + 
 + Primary Completion Date:   December 9, 2022 
 + 
 + Completion Date:       December 9, 2023 
 + 
 + First Posted:         December 17, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      January 26, 2021 
 + 
 + Locations:          The Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04671459 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 2: 
 + 
 + NCT Number:          NCT03258021 
 + 
 + Title:            TTFields In GErmany in Routine Clinical Care 
 + 
 + Acronym:           TIGER 
 + 
 + Status:            Active, not recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma 
 + 
 + Interventions:        Device: TTFields 
 + 
 + Outcome Measures:       Time to death of any cause (overall survival (OS)) from diagnosis|Number of TTFields treatment-related serious adverse events (SAEs) standardized to one year of FU time|Number of SAEs after start of TTFields treatment|Time of usage (compliance) of TTFields treatment over time|Time to first progression of GBM (progression-free survival (PFS)), defined within radiological and/or clinical/neurological assessment during routine clinical care in patients who started TTFields treatment at baseline|Changes in quality of life at month 2 and month 4 after start of TTFields treatment compared to baseline in patients who started TTFields treatment at baseline|Patients' reason(s) for refusing TTFields at baseline 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:             
 + 
 + Enrollment:          710 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Observational 
 + 
 + Study Designs:        Observational Model: Other|Time Perspective: Prospective 
 + 
 + Other IDs:          05.07.2017 
 + 
 + Start Date:          August 31, 2017 
 + 
 + Primary Completion Date:   June 2021 
 + 
 + Completion Date:       July 2021 
 + 
 + First Posted:         August 22, 2017 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      January 28, 2021 
 + 
 + Locations:          Clinical center Aschaffenburg-Alzenau, Aschaffenburg, Bavaria, Germany 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03258021 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 3: 
 + 
 + NCT Number:          NCT04717739 
 + 
 + Title:            TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study 
 + 
 + Acronym:            
 + 
 + Status:            Not yet recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma 
 + 
 + Interventions:        Device: TTFields 
 + 
 + Outcome Measures:       Time of usage of TTFields treatment in follow-up derived from monitoring data of the devices, standardised to usage days, as measure of compliance with TTFields treatment.|Number of TTFields treatment-related SAEs as assessed by the CEC standardized to one year of FU time|Changes in daily physical activity as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy|Changes in sleep quality as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy|Changes in neurocognitive functioning as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy. 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:             
 + 
 + Enrollment:          500 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Observational 
 + 
 + Study Designs:        Observational Model: Other|Time Perspective: Prospective 
 + 
 + Other IDs:          13.01.2021 
 + 
 + Start Date:          March 2021 
 + 
 + Primary Completion Date:   June 1, 2023 
 + 
 + Completion Date:       July 1, 2023 
 + 
 + First Posted:         January 22, 2021 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      January 22, 2021 
 + 
 + Locations:          University Hospital Essen, Essen, Germany 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04717739 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 4: 
 + 
 + NCT Number:          NCT02973789 
 + 
 + Title:            Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Nonsmall Cell Lung Cancer 
 + 
 + Interventions:        Device: NovoTTF-100L|Drug: Immune checkpoint inhibitors or docetaxel 
 + 
 + Outcome Measures:       Overall survival of patients treated with TTFields + docetaxel or immune checkpoint inhibitors vs. docetaxel or immune checkpoint inhibitors alone (superiority analysis)|Overall survival of patients treated with TTFields + docetaxel vs. docetaxel alone (superiority analysis)|Overall survival of patients treated with TTFields + immune checkpoint inhibitors vs. immune checkpoint inhibitors alone (superiority)|Overall Survival of patients treated with TTFields + docetaxel Vs. immune checkpoint inhibitors alone (non-inferiority analysis)|Progression-free survival of patients treated with docetaxel or immune checkpoint inhibitors + TTFields vs. docetaxel or immune checkpoint inhibitors alone, based on RECIST Criteria|Overall radiological response rate (based on RECIST criteria) of patients treated with docetaxel or Immune checkpoint inhibitors + TTFields vs. docetaxel or immune checkpoint inhibitors alone.|Quality of life using the EORTC QLQ C30 questionnaire with LC13 addendum|Analyses of the effects of NovoTTF-100L with each type of immune checkpoint inhibitor on overall survival and progression free survival|Analysis of the effects of NovoTTF-100L on overall survival and progression free survival within each histological subgroup (squamous and non-squamous)|The effect of treatment compliance with NovoTTF-100L on overall survival and progression free survival outcomes|Adverse events, severity and frequency based on Common Terminology Criteria for Adverse Events (CTCAE) V4.03 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 3 
 + 
 + Enrollment:          534 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-24 
 + 
 + Start Date:          December 2016 
 + 
 + Primary Completion Date:   September 2023 
 + 
 + Completion Date:       September 2023 
 + 
 + First Posted:         November 25, 2016 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      March 24, 2021 
 + 
 + Locations:          Central Alabama Research, Birmingham, Alabama, United States|Ironwood Cancer & Research Center, Chandler, Arizona, United States|Cancer Center at St. Joseph Hospital and Medical Center, Phoenix, Arizona, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|California Cancer Associates for Research and Excellence, Inc. cCARE, Fresno, California, United States|Saddleback Memorial Medical Center, Laguna Hills, California, United States|Dignity Health - Mercy Cancer Centers, Sacramento, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Banner MD Anderson Cancer Center at North Colorado Medical Center, Greeley, Colorado, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Adult Oncology Research, Orlando, Florida, United States|BRCR Medical Center INC, Plantation, Florida, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Illinois CancerCare, P.C., Peoria, Illinois, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University Medical Center, Inc; DBA University of Louisville, Louisville, Kentucky, United States|Tulane Cancer Center, New Orleans, Louisiana, United States|CHRISTUS Health, Shreveport, Louisiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Division of Hematology and Oncology, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Clinical Oncology Associates, Farmington Hills, Michigan, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Saint Joseph Mercy Health System, Ypsilanti, Michigan, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CHI Health Research Center, Omaha, Nebraska, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Renown Regional Medical Center Institute for Cancer, Reno, Nevada, United States|Presbyterian Cancer Center, Albuquerque, New Mexico, United States|New York-Presbyterian/Queens Radiation Oncology, Flushing, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|W.G. Bill Hefner VA Med Center, Salisbury, North Carolina, United States|Piedmont Radiation Oncology, PA, Winston-Salem, North Carolina, United States|Summa Health, Akron, Ohio, United States|Toledo Clinic Cancer Center, Toledo, Ohio, United States|Vita Medical Associates, P.C., Bethlehem, Pennsylvania, United States|Geisinger Cancer Institute, Danville, Pennsylvania, United States|UT/Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology - Arlington, Arlington, Texas, United States|Christus Health Spohn Ministry, Corpus Christi, Texas, United States|Dallas VA Medical Center, Dallas, Texas, United States|Texas Oncology- Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Oncology Consultants, P.A., Houston, Texas, United States|Texas Oncology-McKinney, McKinney, Texas, United States|Texas Oncology - Paris, Paris, Texas, United States|Texas Oncology- Plano West, Plano, Texas, United States|Baylor Scott & White Health/McClinton Cancer Center, Waco, Texas, United States|Texas Oncology-Waco, Waco, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Overlake Medical Center & Clinics, Bellevue, Washington, United States|UW Carbone Cancer Center, Madison, Wisconsin, United States|Uniklinikum Salzburg Landeskrankenhaus - Universitätsklinik für Innere Medizin III der PMU, Salzburg, Austria|Institut Jules Bordet - Department of Intensive Care and Thoracic Oncology, Brussels, Belgium|André Renard Clinic, Herstal, Belgium|AZ Sint Maarten, Mechelen, Belgium|McGill University Health Centre, Montréal, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada|Allan Blair Cancer Center, Regina, Saskatchewan, Canada|Thomayerova Nemocnice Dept. of Pneumology, Prague, Czechia|Všeobecná Fakultní Nemocnice, Prague, Czechia|Vitkovicka nemocnice, Vitkovice, Czechia|Centre Hospitalier de Beauvais, Beauvais, France|INSTITUT BERGONIE Centre Régional de Lutte Contre le Cancer, Bordeaux, France|Hospital Centre of Brittany SUDF (CHBS), Lorient, France|CHU de Nîmes ICG. - Service de pneumologie, Nîmes, France|Hôpital Saint-Louis, Paris, France|Hospital Centre of Saint-Quentin, Saint-Quentin, France|Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV Onkologie/Hämatologie, Halle (Saale), Germany|Azienda Sociosanitaria Ligure 3 (ASL 3), Genova, Italy|IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy|UOC Oncologia Medica Presidio Ospedaliero di Ravenna, Ravenna, Italy|ASST della Valle Olona - Presidio Ospedaliero di Saronno, Saronno, Italy|St Jansdal Ziekenhuis, Harderwijk, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|MS Clinsearch Specjalistyczny NZOZ, Lublin, Poland|Katedra i Klinika Onkologii; Szpital Kliniczny Przemienienia Pańskiego UM w Poznaniu, Poznan, Poland|Samodzielny Publiczny Wojewódzki Szpital Zespolony w Szczecinie, Oddział Onkologii Klinicznej i Chemioterapii, Szczecin, Poland|Centrum Terapii Współczesnej, Łódź, Poland|Hospital Universitario Arnau de Vilanova, Lleida, Catalonia, Spain|Hospital Quirón Teknon, Instituto Oncológico Dr. Rosell, Barcelona, Spain|HGU Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Universitario Málaga Regional. IBIMA, Málaga, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Universitari i Politécnic La Fe, Valencia, Spain|KS Winterthur, Medizinische Onkologie, Winterthur, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT02973789 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 5: 
 + 
 + NCT Number:          NCT04492163 
 + 
 + Title:            Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma Multiforme 
 + 
 + Interventions:        Device: TTFields 
 + 
 + Outcome Measures:       Progression free survival (PFS)|Overall Survival (OS)|Progression Free Survival at 6 months (PFS6)|1-year and 2-year survival rates|Overall radiological response|Severity and frequency of adverse events|Pathological changes in resected GBM tumors following study treatment|Dependence of Progression Free Survival on TTFields dose delivered to the tumor bed|Dependence of Overall Survival on TTFields dose delivered to the tumor bed 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          25 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-33 
 + 
 + Start Date:          July 14, 2020 
 + 
 + Primary Completion Date:   January 2022 
 + 
 + Completion Date:       January 2022 
 + 
 + First Posted:         July 30, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      November 24, 2020 
 + 
 + Locations:          Nemocnice Na Homolce, Prague, Czechia 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04492163 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 6: 
 + 
 + NCT Number:          NCT03606590 
 + 
 + Title:            Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) 
 + 
 + Acronym:            
 + 
 + Status:            Active, not recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Hepatocellular Carcinoma 
 + 
 + Interventions:        Device: NovoTTF-100L(P) device|Drug: Sorafenib 
 + 
 + Outcome Measures:       Overall response rate|In-field control rate at one year|Overall survival|Progression Free Survival|Distant metastases-free survival rate at 1 year|Overall survival at one year|Progression free survival at 6 and 12 months|Severity and frequency of adverse events 
 + 
 + Sponsor/Collaborators:    NovoCure GmbH|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          25 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-30 
 + 
 + Start Date:          February 15, 2019 
 + 
 + Primary Completion Date:   September 2021 
 + 
 + Completion Date:       September 2021 
 + 
 + First Posted:         July 31, 2018 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      July 29, 2020 
 + 
 + Locations:          University Hospital Fakultni Nemocnice Olomouc, Oncology Clinic, Olomouc, Czechia|CHU de Nantes, Nantes Cedex 01, France|University Medical Center - University of Freiburg, Freiburg, Germany|Ulm University Hospital, Ulm, Germany|Università Campus Bio-Medico di Roma, Rome, Italy|Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain|HM Hospitales - Centro Integral Oncológico Clara Campal, Madrid, Spain 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03606590 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 7: 
 + 
 + NCT Number:          NCT03377491 
 + 
 + Title:            Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Pancreas Adenocarcinoma 
 + 
 + Interventions:        Device: NovoTTF-100L(P)|Drug: Gemcitabine|Drug: nab paclitaxel 
 + 
 + Outcome Measures:       Overall survival|Progression-free survival|Local progression-free survival|Objective response rate|One-year survival rate|Quality of life|Pain-free survival|Puncture-free survival|Resectability rate|Toxicity profile 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 3 
 + 
 + Enrollment:          556 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-27 
 + 
 + Start Date:          May 10, 2018 
 + 
 + Primary Completion Date:   September 2023 
 + 
 + Completion Date:       September 2023 
 + 
 + First Posted:         December 19, 2017 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      March 11, 2021 
 + 
 + Locations:          Grandview Medical Center, Cancer Center, Birmingham, Alabama, United States|Infirmary Cancer Care, Mobile, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncology Associates, PC- HOPE - US Oncology Research, Tucson, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Pacific Cancer Medical Center, Anaheim, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Dignity Health - Mercy Cancer Centers, Sacramento, California, United States|Sutter Cancer Center Sacramento, Sacramento, California, United States|Boca Raton Regional Hospital, Lynn Cancer Institute, Boca Raton, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|AdventHealth Neuro Oncology, Orlando, Florida, United States|BRCR Medical Center INC, Plantation, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Hospital Tampa, Tampa, Florida, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|Illinois Cancer Specialist - US Oncology Research, Arlington Heights, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Cancer Center, Fairway, Kansas, United States|Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Central Maine Medical Center, Clinical Research Department, Lewiston, Maine, United States|University of Maryland Comprehensive Cancer Center, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A - US Oncology Research, Columbia, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Cancer and Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|MidAmerica Division, Kansas City, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Kaleida Health, Buffalo, New York, United States|NYU Langone Arena Oncology, Lake Success, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Willamette Valley Cancer Institute and Research Center - US Oncology Research, Eugene, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Vita Medical Associates, P.C., Fountain Hill, Pennsylvania, United States|UT/Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology - Beaumont Mamie McFaddin Ward Cancer Center - US Oncology Research, Beaumont, Texas, United States|Texas Oncology - Bedford - US Oncology Reasearch, Bedford, Texas, United States|Methodist Regional Cancer Center, Dallas, Texas, United States|Texas Oncology - Baylor - US Oncology Research, Dallas, Texas, United States|Texas Oncology - El Paso Cancer Treatment Center Gateway - US Oncology Research, El Paso, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Baylor Scott and White Medical Center, Temple, Texas, United States|Texas Oncology - Tyler - US Oncology Research, Tyler, Texas, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - US Oncology Research, Roanoke, Virginia, United States|Vista Oncology Inc PS, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, United States|Medical University Graz, Graz, Austria|Univ. Klinik für Innere Medizin III der PMU, Salzburg, Austria|Landes-Krankenhaus Steyr, Steyr, Austria|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Centre Hospitalier de I'Universitaire de de Montreal (CHUM), Montréal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada|University Hospital Centre Zagreb, Zagreb, Croatia|Nemocnice Nový Jičín, Nový Jičín, Czechia|University Hospital Olomouc, Olomouc, Czechia|General University Hospital in Prague, Praha 2, Czechia|Nemocnice Na Bulovce, Praha 8, Czechia|Hopital haut-Léveque CHU Bordeaux - Service d'Hépato- Gastroentérologie et d'Oncologie digestive, Pessac, Bordeaux, France|Institut de Cancérologie de l'Ouest, Angers cedex, France|Centre Hospitalier de Bretagne Sud /Site du Scorff, Lorient, France|Centre Léon Bérard, Lyon, France|Service d'Oncologie médicale du Pr. Andre, Hôpital Saint-Antoine, Paris, France|Hôpital Privé des Côtes d'Armor, Plérin, France|Clinique Sainte Anne - Groupe Hospitalier Saint-Vincent, Strasbourg Oncologie Libérale, Strasbourg, France|Queen Mary Hospital, Hong Kong, Hong Kong|National Institute of Oncology, Budapest, Hungary|Bekes County Hospital, Gyula, Hungary|Bacs-Kiskun County Hospital, Kecskemét, Hungary|Tolna County Hospital, Szekszárd, Hungary|Jasz-Nagykun-Szolnok County Hospital, Szolnok, Hungary|Rambam Health Care Campus, Oncology Institute, Haifa, Israel|Sourasky Medical Center, Oncology Department, Tel Aviv, Israel|A.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Università Campus Bio-Medico di Rome, Roma, Italy|A.O.U Città della Salute e della Scienza di Torino, Torino, Italy|Oncology Clinic Clinical Hospital of Przemienienia Pańskiego UM in Poznaniu, Poznań, Poland|Centrum Medyczne MrukMed, Rzeszów, Poland|Oncology and Radiotherapy Clinic, Oncology Center - Institute, Warsaw, Poland|Instituto Oncòlogico Dr. Rosell, Barcelona, Spain|Vall d´Hebron University Hospital, Barcelona, Spain|Hospital General Universitario de Elche, Elche, Spain|HM Hospitales - Centro Integral Oncologico Clara Campal - CIOCC, Madrid, Spain|Hospital Universitario Carlos Haya de Malaga, Málaga, Spain|Clinica Universiatria de Navarra, Pamplona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Instituto Valenciano de Oncología IVO, Valencia, Spain|Hôpital Fribourgeois/Freiburger Spital, Fribourg, Switzerland|KS Winterthur, Winterthur, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03377491 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 8: 
 + 
 + NCT Number:          NCT04689087 
 + 
 + Title:            A Prospective, Open-label, Single-arm Clinical Study 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Recurrent Glioblastoma Multiforme 
 + 
 + Interventions:        Combination Product: TTFields 
 + 
 + Outcome Measures:       OS6|Overall survival at 12 months (OS12)|overall survival OS(refers to the time from enrollment to tumor disease death from various causes)|Progression-free survival PFS|security 
 + 
 + Sponsor/Collaborators:    Sun Yat-sen University 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Not Applicable 
 + 
 + Enrollment:          40 
 + 
 + Funded Bys:          Other 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 
 + 
 + Other IDs:          M-TTFields 
 + 
 + Start Date:          April 1, 2020 
 + 
 + Primary Completion Date:   July 1, 2021 
 + 
 + Completion Date:       July 1, 2022 
 + 
 + First Posted:         December 30, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      December 30, 2020 
 + 
 + Locations:          Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04689087 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 9: 
 + 
 + NCT Number:          NCT02397928 
 + 
 + Title:            Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) 
 + 
 + Acronym:            
 + 
 + Status:            Completed 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Malignant Pleural Mesothelioma 
 + 
 + Interventions:        Device: NovoTTF-100L device|Drug: Pemetrexed|Drug: Cisplatin or Carboplatin 
 + 
 + Outcome Measures:       Overall Survival|Progression Free Survival|Response Rate|Toxicity- incidence of adverse events 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          82 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-23 
 + 
 + Start Date:          February 2015 
 + 
 + Primary Completion Date:   April 2018 
 + 
 + Completion Date:       April 2018 
 + 
 + First Posted:         March 25, 2015 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      September 25, 2018 
 + 
 + Locations:          Antwerp University Hospital, Thoracic Oncology, Antwerp, Belgium|Goustave Roussy - Cancer Campus Grand Paris, Villejuif, France|Universitätsklinikum Halle (Saale), Halle, Germany|A.S.O. "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy|Cliniche Humanitas Gavazzeni, Bergamo, Italy|Ospedale Villa Scassi, Genoa, Italy|Ospedaliera di Perugia, Perugia, Italy|Ospedaliero Universitaria Pisana, Pisa, Italy|Erasmus Mc, Rotterdam, Netherlands|Medical University Gdansk, Gdansk, Poland|Katedra i Klinika Onkologii Uniwersytetu Medycznegi im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Klinika Nowotworów Pluca I Klatki Piersiowej, Warsaw, Poland|Vall d' Hebron Institute of Oncology (VHIO) Hospital Vall d'Hebron, Barcelona, Spain 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT02397928 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 10: 
 + 
 + NCT Number:          NCT03940196 
 + 
 + Title:            Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Ovarian Cancer 
 + 
 + Interventions:        Device: NovoTTF-100L(O)|Drug: Paclitaxel 
 + 
 + Outcome Measures:       Overall survival|Progression-free survival|Objective response rate|Next progression-free survival|Time to undisputable deterioration in health-related quality of life (HRQoL)|Time to first and second subsequent treatment|Quality of life using the EORTC QLQ C30 questionnaire with the ovarian cancer symptom OV28 module.|Severity and frequency of adverse events 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            Female 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 3 
 + 
 + Enrollment:          540 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-28 
 + 
 + Start Date:          March 22, 2019 
 + 
 + Primary Completion Date:   September 2023 
 + 
 + Completion Date:       September 2023 
 + 
 + First Posted:         May 7, 2019 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      March 29, 2021 
 + 
 + Locations:          Arizona Oncology- Biltmore Cancer Center, Phoenix, Arizona, United States|Arizona Oncology, Tucson, Arizona, United States|California Pacific Medical Center- Pacific Campus, San Francisco, California, United States|Olive View - UCLA Medical Center, Sylmar, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, Parker, Colorado, United States|Rocky Mountain Cancer Centers, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers, Thornton, Colorado, United States|AdventHealth Cancer Institute, Orlando, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Rush University Cancer Center - Chicago and Innovation, Chicago, Illinois, United States|Des Moines Oncology Research Association, Des Moines, Iowa, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Maryland Oncology Hematology, P.A., Silver Spring, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|Minnesota Oncology Hematology, PA, Saint Paul, Minnesota, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Center of Hope at Renown Medical Center, Reno, Nevada, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Miami Valley Hospital South, Centerville, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|West Penn OB/GYN, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Abington Hospital- Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Sanford Gynecologic Oncology Clinic, Sioux Falls, South Dakota, United States|Texas Oncology Austin-Balcones, Austin, Texas, United States|Texas Oncology Austin-Midtown, Austin, Texas, United States|Texas Oncology Austin-North Austin, Austin, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth, Fort Worth, Texas, United States|The University of Texas Medical School at Houston, Houston, Texas, United States|Texas Oncology-McAllen, McAllen, Texas, United States|Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology - Sugar Land, Sugar Land, Texas, United States|Texas Oncology, The Woodlands, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Carilion Clinic-Gynecologic Oncology, Roanoke, Virginia, United States|Multicare Institute for Research and Innovation, Tacoma, Washington, United States|KH der Barmherzigen Brüder Graz, Graz, Austria|Univ.-Klinik für Gynäkologie und Geburtshilfe, Graz, Austria|Univ.-Klinik für Gynäkologie und Geburtshilfe, Innsbruck, Innsbruck, Austria|Landesfrauenklinik Salzburg, Salzburg, Austria|Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium|Cliniques Universitaires Saint Luc, Institut Roi Albert II, Brussel, Belgium|Grand Hôpital de Charleroi, Oncologie-Hématologie, Charleroi, Belgium|AZ Maria Middelares, Clinical Trial Unit Medical Oncology - Integrated Cancer Center Ghent, Gent, Belgium|UZ Gent, Gent, Belgium|University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium|CHU Ambroise Paré, Mons, Belgium|CHU UCL Namur - Site Ste Elisabeth, Namur, Belgium|UCL-CUL Mont Godinne, Yvoir, Belgium|Onkologická Klinika Fakultní nemocnice Olomouc, Olomouc, Czechia|University Hospital Ostrava, Ostrava-Poruba, Czechia|Gynekologicko-porodnická klinika, Fakultní nemocnice Královské Vinohrady, Praha 10, Czechia|Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha 2, Czechia|Gynekologicko-porodnické oddělení - Nemocnice České Budějovice a.s., České Budějovice, Czechia|Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Gynäkologie, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Horst-Schmidt-Kliniken, Gynecology and Gynecologic, Oncology Department, Wiesbaden, Germany|Nőgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary|Szuleszeti és Nogyogyaszati Klinika, Debrecen, Hungary|Hillel Yaffe Medical Center, Hadera, Israel|Saare Zedek Medical Center - Gyneco-Oncology, Jerusalem, Israel|Oncology Institute, Galilee Medical Center, Nahariya, Israel|Gyneco-Oncology Chaim Sheba Medical Center, Ramat Gan, Israel|Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii, Bologna, Italy|Presidio Ospedaliero Antonio Perrino - ASL Brindisi, Brindisi, Italy|ASST Lecco - Ospedale Manzoni, Dipartimento Oncologico, Lecco, Italy|Dipartimento Medicina e Chirurgia, Università Milano-Bicocca, Direttore Programma Ginecologia Oncologica, Istituto Europeo Oncologia, Milano, Italy|IRCCS Ospedale San Raffaele, U.O. Ginecologia-Ematologia e TMO, Milano, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy|Fondazione Policlinico Universitario Gemelli, Roma, Italy|University Saint Anna, Torino, Italy|Oddział Kliniczny Chirurgii Ogólnej i Onkologicznej, Szpital Św. Rafała, Kraków, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie, Oddział Kliniczny Onkologii i Immunoonkologii z Ośrodkiem Dziennym Terapii Onkologicznej, Olsztyn, Poland|Oddział Ginekologii Onkologicznej Katedry i Kliniki Onkologii Uniwersytetu Medycznego w Poznaniu, Poznań, Poland|Servicio de Oncología Médica, Hospital Universitario Quirón Dexeus, Barcelona, Spain|lnstitut Catala d'Oncologia, Hospital Universitario Dr. Josep Trueta, Servicio de Oncologia,, Girona, Spain|Clinica Universidad de Navarra en Madrid, Madrid, Spain|Hospital MD Anderson Cancer Center, Madrid, Spain|Hospital Universitario Ramon y Cajal, Servicio de Oncologia Médica, Madrid, Spain|Hospital 12 de Octubre. Servicio Oncología Médica, Madrid, Spain|Fundació Institut d'Investigació Sanitària Illes Balears - IdISBa, Hospital Universitari Son Espases, Palma De Mallorca, Spain|Gynecological Tumor Center, University Hospital Basel, Basel, Switzerland|IOSI Bellinzona, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland|Kantonsspital Frauenfeld - Frauenklinik, Frauenfeld, Switzerland|UniversitätsSpital Zürich - Klinik für Gynäkologie, Zürich, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03940196 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 11: 
 + 
 + NCT Number:          NCT03995667 
 + 
 + Title:            Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Extensive Stage Lung Small Cell Carcinoma|Limited Stage Lung Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 
 + 
 + Interventions:        Other: Questionnaire Administration|Device: Tumor Treating Fields Therapy 
 + 
 + Outcome Measures:       Incidence of small cell lung cancer (SCLC) brain metastases at 6 months|Incidence of SCLC brain metastases at 12 months|Overall survival|Incidence of TTfield related adverse events|Incidence of cognitive adverse events (AEs) using Mini Mental State Exam (MMSE)|Change in quality of life over time: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30)|Incidence of SCLC brain metastases 
 + 
 + Sponsor/Collaborators:    OHSU Knight Cancer Institute|NovoCure Ltd.|Oregon Health and Science University 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          106 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 
 + 
 + Other IDs:          STUDY00018029|NCI-2020-00574 
 + 
 + Start Date:          June 11, 2019 
 + 
 + Primary Completion Date:   June 20, 2021 
 + 
 + Completion Date:       December 30, 2022 
 + 
 + First Posted:         June 24, 2019 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      December 16, 2020 
 + 
 + Locations:          Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|University of Washington Medical Center, Seattle, Washington, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03995667 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 12: 
 + 
 + NCT Number:          NCT01971281 
 + 
 + Title:            Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) 
 + 
 + Acronym:            
 + 
 + Status:            Unknown status 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Pancreatic Adenocarcinoma 
 + 
 + Interventions:        Device: NovoTTF-100L|Drug: Gemcitabine|Drug: nab-Paclitaxel 
 + 
 + Outcome Measures:       Adverse Events Severity and Frequency|Feasibility based on compliance with TTFields therapy|Progression Free Survival|Overall Survival|1 Year Survival Rate|6 Month Progression-Free Survival Rate|Overall Response Rate based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria 1.1. 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1|Phase 2 
 + 
 + Enrollment:          40 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-20 
 + 
 + Start Date:          November 2013 
 + 
 + Primary Completion Date:   December 2017 
 + 
 + Completion Date:       December 2017 
 + 
 + First Posted:         October 29, 2013 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      September 13, 2017 
 + 
 + Locations:          Hospital General Universitario de Elche, Elche, Spain|Hospital 12 de Octubre, Madrid, Spain|Ramon Y Cajal, Madrid, Spain|Hospital Universitario Carlos Haya, Malaga, Spain|Hospital Universitario Santander, Santander, Spain|HFR-Hopital Cantonal, Freiburg, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT01971281 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 13: 
 + 
 + NCT Number:          NCT04281576 
 + 
 + Title:            Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Gastric Cancer|GastroEsophageal Cancer 
 + 
 + Interventions:        Device: NovoTTF-100L(P)|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Trastuzumab 
 + 
 + Outcome Measures:       Objective response rate|Progression-free survival|Overall survival|Disease control rate|Time to progression|Duration of response|12 month overall survival rate|Severity and frequency of adverse events 
 + 
 + Sponsor/Collaborators:    NovoCure GmbH|Zai Lab (Shanghai) Co., Ltd.|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Not Applicable 
 + 
 + Enrollment:          28 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-31 / ZL-8301-001 
 + 
 + Start Date:          December 19, 2019 
 + 
 + Primary Completion Date:   September 2021 
 + 
 + Completion Date:       September 2021 
 + 
 + First Posted:         February 24, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      June 25, 2020 
 + 
 + Locations:          Queen Mary Hospital, Hong Kong, Hong Kong 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04281576 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 14: 
 + 
 + NCT Number:          NCT03405792 
 + 
 + Title:            Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) 
 + 
 + Acronym:           2-THE-TOP 
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma|Glioblastoma, WHO Grade IV 
 + 
 + Interventions:        Drug: Temozolomide (TMZ)|Device: Optune System|Drug: Pembrolizumab 
 + 
 + Outcome Measures:       Progression-free survival between the groups|Number of adverse events|Overall Survival (OS)|Augmentation of TTFields-initiated glioma-specific immune reaction by pembrolizumab 
 + 
 + Sponsor/Collaborators:    University of Florida|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years to 80 Years   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          32 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          IRB201702270|OCR16397 
 + 
 + Start Date:          February 23, 2018 
 + 
 + Primary Completion Date:   February 2023 
 + 
 + Completion Date:       February 2023 
 + 
 + First Posted:         January 23, 2018 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      February 9, 2021 
 + 
 + Locations:          University of Florida Health, Gainesville, Florida, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03405792 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 15: 
 + 
 + NCT Number:          NCT04218019 
 + 
 + Title:            Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation 
 + 
 + Acronym:           GERAS 
 + 
 + Status:            Not yet recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Newly Diagnosed Glioblastoma in Patients ≥70 Years 
 + 
 + Interventions:        Device: TTFields 
 + 
 + Outcome Measures:       Safely conducted therapy rate (SCTR)|Number of participants with treatment related adverse events as assessed by CTCAE V 5.0.|Progression-free survival|The correlation between the Optune device usage and the health-related quality of life of elderly patients and families undergoing this therapy in combination with radiotherapy/chemo-radiotherapy. 
 + 
 + Sponsor/Collaborators:    Juergen Debus|University Hospital Heidelberg 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          68 
 + 
 + Funded Bys:          Other 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          GERAS 
 + 
 + Start Date:          August 1, 2021 
 + 
 + Primary Completion Date:   February 1, 2022 
 + 
 + Completion Date:       February 1, 2023 
 + 
 + First Posted:         January 6, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      September 11, 2020 
 + 
 + Locations:          University Hospital of Heidelberg, Radiation Oncology, Heidelberg, Germany 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04218019 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 16: 
 + 
 + NCT Number:          NCT03906448 
 + 
 + Title:            FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma 
 + 
 + Acronym:           FORWARD 
 + 
 + Status:            Terminated 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Astrocytoma, Grade II|Astrocytoma, Grade III 
 + 
 + Interventions:        Combination Product: TTFields with adjuvant temozolomide 
 + 
 + Outcome Measures:       Overall Survival 
 + 
 + Sponsor/Collaborators:    University of Florida|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years to 99 Years   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          2 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          IRB201800600|OCR17711 
 + 
 + Start Date:          May 20, 2019 
 + 
 + Primary Completion Date:   June 8, 2020 
 + 
 + Completion Date:       June 8, 2020 
 + 
 + First Posted:         April 8, 2019 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      June 17, 2020 
 + 
 + Locations:          UF Health at the University of Florida, Gainesville, Florida, United States|USF Health Morsani College of Medicine-Moffitt Cancer Center, Tampa, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|Brown University-Rhode Island Hospital, Providence, Rhode Island, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03906448 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 17: 
 + 
 + NCT Number:          NCT04221503 
 + 
 + Title:            Niraparib/TTFields in GBM 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma|Recurrent Glioblastoma|GBM 
 + 
 + Interventions:        Drug: Niraparib|Device: Optune|Procedure: Planned surgical resection 
 + 
 + Outcome Measures:       Disease control, defined as achievement of either CR, PR, or SD, as defined by modified Response Assessment in Neuro-Oncology (mRANO) criteria.|Number of AEs (Adverse Events)|Duration of disease control.|Objective radiographic response (ORR)|Progression-free survival (PFS)|Overall survival (OS) 
 + 
 + Sponsor/Collaborators:    University of Pennsylvania|Tesaro, Inc.|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          30 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          03319 
 + 
 + Start Date:          December 30, 2019 
 + 
 + Primary Completion Date:   December 2025 
 + 
 + Completion Date:       December 2025 
 + 
 + First Posted:         January 9, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      July 2, 2020 
 + 
 + Locations:          Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04221503 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 18: 
 + 
 + NCT Number:          NCT02831959 
 + 
 + Title:            Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fileds (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Brain Metastases From Non-small Cell Lung Cancer (NSCLC) 
 + 
 + Interventions:        Device: NovoTTF-100M device|Other: Best Standard of Care 
 + 
 + Outcome Measures:       Time to intracranial progression|Time to neurocognitive failure|Overall survival|Radiological response in the brain|Time to second intracranial progression|Time to first and second intracranial progression evaluated in two cohorts, 1-4 brain metastases and 5-10 brain metastases.|Rate of intracranial progression at 2, 4, 6, 8, 10, 12 months|Time to distant progression|Rate of decline in cognitive function at 2, 4, 6, 8, 10, 12 months|Neurocognitive failure-free survival|Quality of Life using the EORTC QLQ C30 with BN20 addendum|Toxicity during NovoTTF-100M treatment based on incidence and severity of treatment emergent adverse events as evaluated using the CTCAE version 4.0 
 + 
 + Sponsor/Collaborators:    NovoCure GmbH|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 3 
 + 
 + Enrollment:          270 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-25 METIS 
 + 
 + Start Date:          July 2016 
 + 
 + Primary Completion Date:   September 2022 
 + 
 + Completion Date:       September 2022 
 + 
 + First Posted:         July 13, 2016 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      January 6, 2021 
 + 
 + Locations:          University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Mayo Clinic Phoenix, Phoenix, Arizona, United States|MemorialCare Cancer Institute, Long Beach, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Redwood City, Redwood City, California, United States|Dignity Health - Mercy Cancer Centers, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Sharp HealthCare, San Diego, California, United States|University of California, San Francisco, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|UF Health Cancer Center, Orlando, Florida, United States|BRCR Medical Center INC, Plantation, Florida, United States|Piedmont Brain Tumor Center, Atlanta, Georgia, United States|CDH-Delnor Health System, Warrenville, Illinois, United States|Ochsner Health System, New Orleans, Louisiana, United States|Willis-Knighton Cancer Center, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|John Nasseff Neuroscience Institute ANW Brain Tumor Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center, University of Missouri Healthcare, Columbia, Missouri, United States|Oncology Research  Mercy Research, Saint Louis, Missouri, United States|Renown Regional Medical Center, Reno, Nevada, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States|UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|West Cancer Center, Germantown, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|Texas Oncology, McKinney, Texas, United States|Texas Oncology, Plano, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States|Medizinische Universität Innsbruck, Innsbruck, Austria|UMHAT Sv. Ivan Rilski EAD, Department of Medical Oncology, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sofiamed, Department of Medical Oncology, Sofia, Bulgaria|Cancercare Manitoba, Winnipeg, Manitoba, Canada|Notre-Dame Hospital CHUM, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Le CIUSSS de I'Est-de-L'ile de Montreal, Montréal, Quebec, Canada|Radiochirugia Zagreb, Sveta Nedelja, Croatia|University Hospital Lille, Lille, France|Clairval Hospital Center, Marseille, France|Hopital Pitié-Salpétriere, Paris, France|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Dr. Senckenbergisches Institut für Neuroonkologie, Zentrum der Neurologie und Neurochirurgie, Frankfurt am main, Germany|Universitätsklinikum Halle (Saale), Klinik für Innere Medizin IV, Hämatologie / Onkologie, Halle (Saale), Germany|Geza Hetenyi Hospital-Clinic of Jasz-Nagykun-Szolnok County, Szolnok, Hungary|Rambam Medical Center, Haifa, Israel|Hadassah Medical Organization, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Sourasky Medical Center, Tel Aviv, Israel|A.O.S.G. Moscati Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialità, Avellino, Italy|Azienda Socio Sanitaria Territoriale di Lecco, Lecco, Italy|University Hospital of Messina AOU Policlinico "G. Martino", Messina, Italy|Marek Harat Private Practice, Neurosurgery and Radiation Oncology, Bydgoszcz, Poland|University Clinical Center, Gdańsk, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Center for Neuro-oncology, Neurosurgery Clinic, Clinical Center of Serbia, Belgrad, Serbia|Catalan Institute of Oncology, Barcelona, Spain|Clinica Universidad de Navarra, Pamplona, Spain 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT02831959 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 19: 
 + 
 + NCT Number:          NCT02663271 
 + 
 + Title:            TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma Multiforme|Glioblastoma|Malignant Glioma|GBM 
 + 
 + Interventions:        Drug: Bevacizumab|Device: Optune|Other: Brain MRI|Other: Quality of Life Questionnaires 
 + 
 + Outcome Measures:       Progression-free survival between the groups|Number of adverse events|Karnofsky Performance Scale|Mini-Mental Status Exam|Response Assessment in Neuro-Oncology (RANO) Measurement Form 
 + 
 + Sponsor/Collaborators:    University of Florida|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          18 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          IRB201600074|OCR14874 
 + 
 + Start Date:          August 2016 
 + 
 + Primary Completion Date:   March 15, 2022 
 + 
 + Completion Date:       March 15, 2022 
 + 
 + First Posted:         January 26, 2016 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      November 3, 2020 
 + 
 + Locations:          University of Florida, Gainesville, Florida, United States|Washington University, Saint Louis, Missouri, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT02663271 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 20: 
 + 
 + NCT Number:          NCT02743078 
 + 
 + Title:            Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma 
 + 
 + Acronym:            
 + 
 + Status:            Terminated 
 + 
 + Study Results:        Has Results 
 + 
 + Conditions:          Glioblastoma|Glioma|Gliosarcoma 
 + 
 + Interventions:        Drug: Bevacizumab|Device: TTFields Therapy 
 + 
 + Outcome Measures:       Overall Survival at 6 Months|Overall Survival (OS)|Progression-Free Survival|Number of Participants With Partial or Complete Response|Number of Participants With Grade 3+ Treatment-related Adverse Events 
 + 
 + Sponsor/Collaborators:    RTOG Foundation, Inc.|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          3 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          RTOG 3503|RF 3503 
 + 
 + Start Date:          May 9, 2017 
 + 
 + Primary Completion Date:   October 15, 2019 
 + 
 + Completion Date:       October 15, 2019 
 + 
 + First Posted:         April 19, 2016 
 + 
 + Results First Posted:     November 17, 2020 
 + 
 + Last Update Posted:      November 17, 2020 
 + 
 + Locations:          University of California, San Diego, La Jolla, California, United States|University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States 
 + 
 + Study Documents:       "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02743078/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02743078/ICF_001.pdf 
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT02743078 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 21: 
 + 
 + NCT Number:          NCT02244502 
 + 
 + Title:            Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) 
 + 
 + Acronym:            
 + 
 + Status:            Unknown status 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Ovarian Carcinoma 
 + 
 + Interventions:        Device: NovoTTF-100L(O)|Drug: Paclitaxel 
 + 
 + Outcome Measures:       Adverse Events Severity and Frequency|Number of patients prematurely discontinuing TTFields due to Skin Toxicity|Progression Free Survival|Overall Survival|1 Year Survival Rate|Overall Radiological Response Rate and Duration of Response|CA-125 Response Rate and Duration of Response|Patients' compliance with TTFields Therapy 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            Female 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1|Phase 2 
 + 
 + Enrollment:          31 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-22 
 + 
 + Start Date:          September 2014 
 + 
 + Primary Completion Date:   December 2016 
 + 
 + Completion Date:       December 2016 
 + 
 + First Posted:         September 19, 2014 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      September 21, 2016 
 + 
 + Locations:          Leuven, Belgium|Charité - Universitätsmedizin Berlin, Berlin, Germany|Hospitale Universitario 12 de Octubre, Madrid, Spain|Ospedale San Giovanni, Bellinzona, Switzerland|Kantonsspital Graubünden, Chur, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT02244502 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 22: 
 + 
 + NCT Number:          NCT03033992 
 + 
 + Title:            Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Malignant Glioma|Ependymoma 
 + 
 + Interventions:        Device: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields) 
 + 
 + Outcome Measures:       The feasibility of treatment with the Optune device in pediatric patients with recurrent/refractory/progressive supratentorial malignant glioma and ependymoma.|The Optune device treatment-related toxicities in children with recurrent/refractory/progressive supratentorial malignant glioma and ependymoma.|The Response Rate|The Event-Free Survival|The association of anti-tumor activity with compliance in Optune device use within the context of a small feasibility study.|The association between the Optune device usage and the health-related quality of life of children and families undergoing this therapy.|The association of apparent diffusion coefficient (ADC) values within the tumor and correlate with response to Optune treatment and EFS. 
 + 
 + Sponsor/Collaborators:    Pediatric Brain Tumor Consortium|National Cancer Institute (NCI) 
 + 
 + Gender:            All 
 + 
 + Age:             5 Years to 21 Years   (Child, Adult) 
 + 
 + Phases:            Not Applicable 
 + 
 + Enrollment:          25 
 + 
 + Funded Bys:          Other|NIH 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          PBTC-048|5UM1CA081457 
 + 
 + Start Date:          April 4, 2017 
 + 
 + Primary Completion Date:   April 2021 
 + 
 + Completion Date:       April 2021 
 + 
 + First Posted:         January 27, 2017 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      February 15, 2021 
 + 
 + Locations:          Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Stewart Goldman, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03033992 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 23: 
 + 
 + NCT Number:          NCT04221061 
 + 
 + Title:            A Pilot Study Evaluating in Vivo PARP-1 Expression with18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Glioblastoma 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma 
 + 
 + Interventions:        Drug: 18F-FluorThanatrace 
 + 
 + Outcome Measures:       Evaluate uptake of [18F]FTT in recurrent glioblastoma after initiation of TTFields therapy.|Correlate [18F]FTT uptake measures with Homologous recombination deficiency (HRD) status or other markers of "BRCAness". 
 + 
 + Sponsor/Collaborators:    University of Pennsylvania 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Early Phase 1 
 + 
 + Enrollment:          12 
 + 
 + Funded Bys:          Other 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic 
 + 
 + Other IDs:          833963 
 + 
 + Start Date:          February 20, 2020 
 + 
 + Primary Completion Date:   December 2, 2021 
 + 
 + Completion Date:       December 2, 2022 
 + 
 + First Posted:         January 9, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      February 12, 2021 
 + 
 + Locations:          University of Pennsylvania, Philadelphia, Pennsylvania, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04221061 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 24: 
 + 
 + NCT Number:          NCT03780569 
 + 
 + Title:            TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM 
 + 
 + Acronym:            
 + 
 + Status:            Unknown status 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma Multiforme 
 + 
 + Interventions:        Device: NovoTTF-200A|Radiation: Radiotherapy|Drug: Temozolomide 
 + 
 + Outcome Measures:       Safety of concomitant Radiotherapy/Temozolomide with NovoTTF-200A: The incidence of Radiotherapy treatment delays during concomitant Radiotherapy/Temozolomide/NovoTTF-200A will be documented including severity and relationship to NovoTTF-200A.|Progression free survival|Overall survival|Adverse events, severity and frequency 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Not Applicable 
 + 
 + Enrollment:          10 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          ICH-1 
 + 
 + Start Date:          April 27, 2017 
 + 
 + Primary Completion Date:   January 2019 
 + 
 + Completion Date:       January 2019 
 + 
 + First Posted:         December 19, 2018 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      December 20, 2018 
 + 
 + Locations:          Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03780569 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 25: 
 + 
 + NCT Number:          NCT01755624 
 + 
 + Title:            Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET) 
 + 
 + Acronym:            
 + 
 + Status:            Unknown status 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          1-5 Brain Metastases From Non-Small Cell Lung Cancer 
 + 
 + Interventions:        Device: NovoTTF-100A device|Other: Best Standard of Care 
 + 
 + Outcome Measures:       Time to Local and Distant Progression in The Brain|Overall Survival|6-Month Disease Control Rate in The Brain|Neurocognitive Function (MMSE and HVLT)|Quality of life (QLQ-C30 and BN-20)|Overall (systemic) Progression-Free Survival (RECIST Criteria)|Adverse Events Severity and Frequency 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          18 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-21 
 + 
 + Start Date:          January 2013 
 + 
 + Primary Completion Date:   July 2017 
 + 
 + Completion Date:       July 2017 
 + 
 + First Posted:         December 24, 2012 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      September 21, 2016 
 + 
 + Locations:          Na Homolce Hospital, Prague, Czech Republic|Hopital Neurologique Pierre Wertheimer, Lyon, France|Centre Paul Strauss, Strasbourg, France|Ospedale Lecco, Lecco, Italy|Medical University of Gdańsk, Gdańsk, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|ICO L'Hospitalet - Hospital Duran i Reynals, Barcelona, Spain 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT01755624 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 26: 
 + 
 + NCT Number:          NCT03223103 
 + 
 + Title:            Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma 
 + 
 + Interventions:        Drug: Poly-ICLC|Device: Tumor Treating Fields|Biological: Peptides 
 + 
 + Outcome Measures:       Dose-limiting toxicities (DLT)|Toxicity grading using CTCAE scale|The percent Progression Free Survival (PFS)|Overall Survival (OS) Rate|Overall Response Rate 
 + 
 + Sponsor/Collaborators:    Adilia Hormigo|NovoCure Ltd.|Icahn School of Medicine at Mount Sinai 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1 
 + 
 + Enrollment:          20 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          GCO 17-0566|16-089 
 + 
 + Start Date:          March 1, 2018 
 + 
 + Primary Completion Date:   May 2023 
 + 
 + Completion Date:       May 2023 
 + 
 + First Posted:         July 19, 2017 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      September 2, 2020 
 + 
 + Locations:          Icahn School of Medicine at Mount Sinai, New York, New York, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03223103 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 27: 
 + 
 + NCT Number:          NCT03705351 
 + 
 + Title:            Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma|Cancer of Brain|Glioblastoma Multiforme|Brain Tumor 
 + 
 + Interventions:        Device: Tumor Treating Fields|Drug: Temozolomide|Radiation: Radiation Therapy 
 + 
 + Outcome Measures:       Rate of treatment-related adverse events associated with trimodal therapy|Severity of treatment-related adverse events associated with trimodal therapy|Progression-free survival at 6 months and 24 months|Overall Survival Rate 
 + 
 + Sponsor/Collaborators:    Providence Health & Services|University of California, San Francisco|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1 
 + 
 + Enrollment:          30 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          UNITYGBM01 
 + 
 + Start Date:          December 2, 2019 
 + 
 + Primary Completion Date:   November 1, 2023 
 + 
 + Completion Date:       November 1, 2025 
 + 
 + First Posted:         October 15, 2018 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      May 28, 2020 
 + 
 + Locations:          University of California San Francisco, San Francisco, California, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03705351 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 28: 
 + 
 + NCT Number:          NCT03353896 
 + 
 + Title:            NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma 
 + 
 + Acronym:            
 + 
 + Status:            Withdrawn 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Anaplastic Oligodendroglioma|Oligoastrocytoma|Oligodendroglioma 
 + 
 + Interventions:        Device: Wear novoTTF-200A|Procedure: Quality-of-Life Assessment 
 + 
 + Outcome Measures:       Safety and Tolerability of the NovoTTFields treatment in patients with high risk oligodendroglioma 
 + 
 + Sponsor/Collaborators:    University of Southern California|National Cancer Institute (NCI)|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             19 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Not Applicable 
 + 
 + Enrollment:          0 
 + 
 + Funded Bys:          Other|NIH|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          6B-15-1|NCI-2017-02074|EF-OLIGO-15|P30CA014089 
 + 
 + Start Date:          December 15, 2017 
 + 
 + Primary Completion Date:   December 8, 2020 
 + 
 + Completion Date:       December 8, 2020 
 + 
 + First Posted:         November 27, 2017 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      December 10, 2020 
 + 
 + Locations:          USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03353896 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 29: 
 + 
 + NCT Number:          NCT02893137 
 + 
 + Title:            Enhancing Optune Therapy With Targeted Craniectomy 
 + 
 + Acronym:            
 + 
 + Status:            Completed 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma 
 + 
 + Interventions:        Device: Optune|Procedure: Craniectomy 
 + 
 + Outcome Measures:       Frequency of serious adverse events|Overall survival|Progression free survival|Progression free survival at six months|% 1-year survival|Objective response rate|Quality of life|Cumulative corticosteroid dosage|Karnofsky performance score 
 + 
 + Sponsor/Collaborators:    Aarhus University Hospital|NovoCure Ltd.|University of Aarhus 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1 
 + 
 + Enrollment:          15 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          54762 
 + 
 + Start Date:          October 1, 2016 
 + 
 + Primary Completion Date:   May 31, 2019 
 + 
 + Completion Date:       May 31, 2019 
 + 
 + First Posted:         September 8, 2016 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      November 27, 2019 
 + 
 + Locations:          Aarhus University Hospital, Aarhus C, Aarhus, Denmark 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT02893137 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 30: 
 + 
 + NCT Number:          NCT03477110 
 + 
 + Title:            Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma 
 + 
 + Interventions:        Drug: Temozolomide|Radiation: Radiation Therapy|Device: NovoTTF-200A Device|Procedure: Tumor Treating Fields Therapy 
 + 
 + Outcome Measures:       NovoTTF-200A device discontinuation rate due to skin toxicity|Progression-free survival|Overall survival|Event-free survival 
 + 
 + Sponsor/Collaborators:    Sidney Kimmel Cancer Center at Thomas Jefferson University|NovoCure Ltd.|Thomas Jefferson University 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Early Phase 1 
 + 
 + Enrollment:          35 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          17P.346 
 + 
 + Start Date:          May 4, 2018 
 + 
 + Primary Completion Date:   March 2021 
 + 
 + Completion Date:       September 2021 
 + 
 + First Posted:         March 26, 2018 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      March 5, 2021 
 + 
 + Locations:          Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03477110 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 31: 
 + 
 + NCT Number:          NCT04397679 
 + 
 + Title:            Partial Brain Radiation Therapy, Temozolomide, Chloroquine, and Tumor Treating Fields Therapy for the Treatment of Newly Diagnosed Glioblastoma 
 + 
 + Acronym:            
 + 
 + Status:            Not yet recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma|Gliosarcoma 
 + 
 + Interventions:        Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: Intensity-Modulated Radiation Therapy (IMRT)|Drug: Temozolomide|Drug: Chloroquine|Procedure: Tumor Treating Fields Therapy (TTF) 
 + 
 + Outcome Measures:       Proportion of patients who develop a specific acute toxicity (dermatitis)|Incidence of adverse events 
 + 
 + Sponsor/Collaborators:    Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1 
 + 
 + Enrollment:          10 
 + 
 + Funded Bys:          Other|NIH 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          2018-148 
 + 
 + Start Date:          April 30, 2021 
 + 
 + Primary Completion Date:   March 11, 2022 
 + 
 + Completion Date:       September 11, 2022 
 + 
 + First Posted:         May 21, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      March 1, 2021 
 + 
 + Locations:          Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04397679 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 32: 
 + 
 + NCT Number:          NCT03687034 
 + 
 + Title:            A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma 
 + 
 + Acronym:            
 + 
 + Status:            Unknown status 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma 
 + 
 + Interventions:        Drug: Temozolomide|Device: Optune 
 + 
 + Outcome Measures:       Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Maximum tolerated dose|Levels of metabolites|Progression-free survival 
 + 
 + Sponsor/Collaborators:    Leaf Vertical Inc. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years to 85 Years   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1 
 + 
 + Enrollment:          21 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          Olympian 2 
 + 
 + Start Date:          June 1, 2019 
 + 
 + Primary Completion Date:   September 30, 2019 
 + 
 + Completion Date:       December 31, 2020 
 + 
 + First Posted:         September 27, 2018 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      February 26, 2019 
 + 
 + Locations:           
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03687034 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 33: 
 + 
 + NCT Number:          NCT04474353 
 + 
 + Title:            Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma 
 + 
 + Acronym:            
 + 
 + Status:            Not yet recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma|Newly Diagnosed Glioblastoma 
 + 
 + Interventions:        Device: Optune|Drug: Gadolinium|Drug: Temozolomide|Radiation: Stereotactic radiosurgery (SRS) 
 + 
 + Outcome Measures:       Dose-limiting Toxicity (DLTs)|Acute dose limiting toxicity|Progression-free Survival (PFS) at 6 Months|Overall Survival (OS) 
 + 
 + Sponsor/Collaborators:    Stanford University|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1 
 + 
 + Enrollment:          12 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          IRB-53582|BRN0043 
 + 
 + Start Date:          November 2020 
 + 
 + Primary Completion Date:   May 2023 
 + 
 + Completion Date:       November 2024 
 + 
 + First Posted:         July 16, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      October 22, 2020 
 + 
 + Locations:          Stanford University, Stanford, California, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04474353 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 34: 
 + 
 + NCT Number:          NCT00749346 
 + 
 + Title:            NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer 
 + 
 + Acronym:            
 + 
 + Status:            Completed 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Non-small Cell Lung Cancer|NSCLC 
 + 
 + Interventions:        Device: NovoTTF-100L 
 + 
 + Outcome Measures:       Device related toxicity|Time to progression 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1|Phase 2 
 + 
 + Enrollment:          42 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-15 
 + 
 + Start Date:          May 2008 
 + 
 + Primary Completion Date:   July 2011 
 + 
 + Completion Date:       July 2011 
 + 
 + First Posted:         September 9, 2008 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      September 27, 2011 
 + 
 + Locations:          CCRC, Basel, Switzerland|Kantonspital Graubunden, Chur, Switzerland|Kantonspital Fribourg, Fribourg, Switzerland|Kantonspital Winterthur, Winterthur, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT00749346 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 35: 
 + 
 + NCT Number:          NCT04469075 
 + 
 + Title:            Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma|Skin Toxicity 
 + 
 + Interventions:        Drug: Clindamycin Phosphate|Drug: Triamcinolone Acetonide 
 + 
 + Outcome Measures:       Number of patients without grade 2 or higher skin toxicity|skin-related quality of life 
 + 
 + Sponsor/Collaborators:    Memorial Sloan Kettering Cancer Center 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          58 
 + 
 + Funded Bys:          Other 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          19-342 
 + 
 + Start Date:          July 9, 2020 
 + 
 + Primary Completion Date:   July 2023 
 + 
 + Completion Date:       July 2023 
 + 
 + First Posted:         July 13, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      April 1, 2021 
 + 
 + Locations:          Northwestern University, Evanston, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04469075 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 36: 
 + 
 + NCT Number:          NCT03980249 
 + 
 + Title:            Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells 
 + 
 + Acronym:            
 + 
 + Status:            Not yet recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma|Glioblastoma Multiforme 
 + 
 + Interventions:        Drug: Carvedilol 
 + 
 + Outcome Measures:       Survival curve of overall survival|Survival curve of progression free survival|Quantify Circulating Tumor Cells (CTCs) 
 + 
 + Sponsor/Collaborators:    West Virginia University|NovoCure Ltd.|West Virginia Clinical and Translational Science Institute 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Early Phase 1 
 + 
 + Enrollment:          30 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          WVU020318 
 + 
 + Start Date:          September 2020 
 + 
 + Primary Completion Date:   December 2021 
 + 
 + Completion Date:       June 2022 
 + 
 + First Posted:         June 10, 2019 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      November 4, 2019 
 + 
 + Locations:          WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States 
 + 
 + Study Documents:       "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03980249/ICF_000.pdf 
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03980249 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 37: 
 + 
 + NCT Number:          NCT03194971 
 + 
 + Title:            NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma 
 + 
 + Interventions:        Other: Tumor samples from patients treated with TTFields at initial diagnosis.|Device: Tumor samples from patients treated with TTFields at tumor recurrence. 
 + 
 + Outcome Measures:       Number of mitotically active cells|Number of mitotically inactive cells|Mitotic Ratio 
 + 
 + Sponsor/Collaborators:    Medical College of Wisconsin 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:             
 + 
 + Enrollment:          20 
 + 
 + Funded Bys:          Other 
 + 
 + Study Type:          Observational 
 + 
 + Study Designs:        Observational Model: Other|Time Perspective: Retrospective 
 + 
 + Other IDs:          PRO00017446 
 + 
 + Start Date:          June 1, 2017 
 + 
 + Primary Completion Date:   May 31, 2021 
 + 
 + Completion Date:       May 31, 2022 
 + 
 + First Posted:         June 21, 2017 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      December 16, 2020 
 + 
 + Locations:          Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03194971 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 38: 
 + 
 + NCT Number:          NCT03607682 
 + 
 + Title:            Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer 
 + 
 + Acronym:            
 + 
 + Status:            Terminated 
 + 
 + Study Results:        Has Results 
 + 
 + Conditions:          Extensive Stage Small Cell Lung Carcinoma 
 + 
 + Interventions:        Procedure: Tumor Treating Fields (TTF) Therapy|Device: NovoTTF-200A Device|Other: Quality-of-Life Assessment 
 + 
 + Outcome Measures:       Percentage of Patients Continuing Therapy Until Intracranial Tumor|Time to Intracranial Failure|Overall Survival|Rate of Intracranial Failure|Rate of Decline in Cognitive Function|Time to Neurocognitive Failure|Neurocognitive Failure-free Survival|Evaluate Quality of Life Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Incidence of Adverse Events 
 + 
 + Sponsor/Collaborators:    Vanderbilt-Ingram Cancer Center|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Not Applicable 
 + 
 + Enrollment:          2 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          VICC THO 1747|NCI-2018-01428 
 + 
 + Start Date:          September 5, 2018 
 + 
 + Primary Completion Date:   June 2, 2020 
 + 
 + Completion Date:       July 13, 2020 
 + 
 + First Posted:         July 31, 2018 
 + 
 + Results First Posted:     August 4, 2020 
 + 
 + Last Update Posted:      August 4, 2020 
 + 
 + Locations:          Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States 
 + 
 + Study Documents:       "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03607682/Prot_SAP_000.pdf 
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03607682 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 39: 
 + 
 + NCT Number:          NCT04223999 
 + 
 + Title:            Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery) 
 + 
 + Acronym:           OptimalTTF-2 
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Recurrent Glioblastoma 
 + 
 + Interventions:        Procedure: Skullremodeling surgery|Other: Control 
 + 
 + Outcome Measures:       OS12|Median OS|Median PFS|OS24|OS36|PFS6|ORR|Standardised and verified quality of life assessment questionnaires (QLQ-C30 and QLQ-BN20) for cancer and brain tumor patients.|Steroid dose|KPS|AE 
 + 
 + Sponsor/Collaborators:    Anders Rosendal Korshøj|NovoCure GmbH|Odense University Hospital|University of Aarhus 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          70 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 
 + 
 + Other IDs:          150919V1|68928/1-10-72-214-19|658876/1-16-02-277-19|2019081231 
 + 
 + Start Date:          October 1, 2020 
 + 
 + Primary Completion Date:   March 1, 2023 
 + 
 + Completion Date:       March 1, 2024 
 + 
 + First Posted:         January 13, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      November 5, 2020 
 + 
 + Locations:          Nikola Mikic, Aarhus, Denmark 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04223999 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 40: 
 + 
 + NCT Number:          NCT00379470 
 + 
 + Title:            Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) 
 + 
 + Acronym:            
 + 
 + Status:            Completed 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Recurrent Glioblastoma Multiforme 
 + 
 + Interventions:        Device: NovoTTF-100A 
 + 
 + Outcome Measures:       Overall Survival|Progression free survival at 6 months (PFS6)|Median Time to Disease Progression (TTP)|% 1-year survival|Radiological response (Macdonald criteria)|Quality of life assessment (EORTC QLQ-C30)|Adverse events severity and frequency 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 3 
 + 
 + Enrollment:          236 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-11 
 + 
 + Start Date:          September 2006 
 + 
 + Primary Completion Date:   November 2009 
 + 
 + Completion Date:       January 2011 
 + 
 + First Posted:         September 21, 2006 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      May 1, 2012 
 + 
 + Locations:          Northwestern University, Chicago, Illinois, United States|University of Illinois in Chicago, Chicago, Illinois, United States|Evanston Northwestern Healthcare, Evanston, Illinois, United States|Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|NJ Neuroscience Institute - JFK Medical Center, Edison, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Hospital Graz, Graz, Austria|FN Brno - Masaryk University, Brno, Czech Republic|Na Homolce Hospital, Prague, Czech Republic|Hospital of Neurology Lyon - University Claude Bernard Lyon 1, Lyon, France|Group Hospitals Pitie-Salpetriere, Paris, France|University Hospital Augsburg, Augsburg, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|University Hospital of Schleswig-Holstein, Kiel, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT00379470 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 41: 
 + 
 + NCT Number:          NCT00916409 
 + 
 + Title:            Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) 
 + 
 + Acronym:            
 + 
 + Status:            Completed 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma Multiforme 
 + 
 + Interventions:        Device: NovoTTF-100A device|Drug: Temozolomide 
 + 
 + Outcome Measures:       Progression Free Survival (PFS) time|Overall survival (OS) 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 3 
 + 
 + Enrollment:          700 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-14 
 + 
 + Start Date:          June 2009 
 + 
 + Primary Completion Date:   December 2016 
 + 
 + Completion Date:       March 2017 
 + 
 + First Posted:         June 9, 2009 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      April 10, 2017 
 + 
 + Locations:          University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|University of California San Diego Moores Cancer Center (UCSD), La Jolla, California, United States|University of Southern California (USC), Los Angeles, California, United States|University of Colorado Denver, Aurora, Colorado, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Emory University, Winship Cancer Institute, Atlanta, Georgia, United States|University of Illinois at Chicago (UIC), Chicago, Illinois, United States|University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Maine Medical Center, Scarborough, Maine, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Division of Oncology, St. Louis, Missouri, United States|New Jersey Neuroscience Center - JFK Medical Center, Edison, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai Medical Center, Department of Neurosurgery, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|The Ohio State University Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Geisinger Health System, Danville, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor, Dallas, Texas, United States|Methodist Hospital, Houston, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|The University of Texas Health Science Center at Houston (UTHSC), Houston, Texas, United States|Scott and White Healthcare, Temple, Texas, United States|Memorial Hermann The Woodlands, The Woodlands, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States|University Hospital Graz, Graz, Austria|Medical University of Vienna, Vienna, Austria|SMZ-Süd/Kaiser-Franz-Josef-Spital, Vienna, Austria|Tom Baker Cancer Center, Calgary, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Juravinski Cancer Centre, Hamilton,, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Notre-Dame Hospital (CHUM), Montreal, Quebec, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada|McGill - Gerald Bronfman Centre for Clinical Research in Oncology -, Montreal, Quebec, Canada|(CHUS) Centre Hospitalier Universitaire de Sherbrooke, Service de Neurochirurgie, Sherbrooke, Quebec, Canada|Na Homolce Hospital, Prague, Czech Republic|CHU Amiens Sud-Salouel, Amiens, France|CHU Angers, Angers, France|Hôpital Saint André Centre Hospitalier Universitaire (CHU) des Hôpitaux de Bordeaux, Bordeaux, France|Hospital of Neurology Pierre Wertheimer, Lyon, France|Group Hospitals Pitie-Salpetriere, Paris, France|Centre Hospitalo-Universitaire de Toulouse Purpan, Toulouse, France|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|Medical University Heidelberg, Heidelberg, Germany|University Hospital of Schleswig-Holstein, Kiel, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Az. Ospedaliero-Universitaria - Ospedali Riuniti, Ancona, Italy|Ospedale Lecco, Lecco, Italy|C. Besta Neurological Institute, Milan, Italy|Foundation Hospital Greater Policlinico, Milan, Italy|Istituti Fisioterapici Ospitalieri - Istituto Nazionale dei Tumori Regina Elena, Rome, Italy|Asan Medical Center, Asan, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital (CNUH), Daejeon, Korea, Republic of|Samsung Medical Center (SMC), Seoul, Korea, Republic of|Seoul National University Bundang Hospital (SNUBH), Seoul, Korea, Republic of|Seoul National University Hospital (SNUH), Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital (CMC Seoul), Seoul, Korea, Republic of|Yonsei University Severance Hospital (YUHS), Seoul, Korea, Republic of|Ajou University Hospital (AUH), Suwon, Korea, Republic of|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari de Bellvitge-ICO Duran i Reynals, Barcelona, Spain|Fundacion Jimenes Diaz, Madrid, Spain|Hospital 12 de Octubre, Servicio de Oncología Médica, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Karolinska Institute, Stockholm, Sweden|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitätsSpital Zürich, Zurich, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT00916409 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 42: 
 + 
 + NCT Number:          NCT01894061 
 + 
 + Title:            NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma 
 + 
 + Acronym:            
 + 
 + Status:            Completed 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor 
 + 
 + Interventions:        Biological: Bevacizumab|Device: NovoTTF-l00A|Other: Quality of Life Assessment 
 + 
 + Outcome Measures:       Progression Free Survival (PFS)|Objective response rate based on RANO Criteria|Number of patients that experience toxicities with this combination of therapies|Median overall survival|To assess time-to-progression|Neurocognitive function (NCF)|Quality of Life (QOL) 
 + 
 + Sponsor/Collaborators:    Case Comprehensive Cancer Center|NovoCure Ltd.|National Cancer Institute (NCI) 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          25 
 + 
 + Funded Bys:          Other|Industry|NIH 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          CASE3313 
 + 
 + Start Date:          June 12, 2013 
 + 
 + Primary Completion Date:   July 28, 2019 
 + 
 + Completion Date:       July 28, 2019 
 + 
 + First Posted:         July 9, 2013 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      July 24, 2020 
 + 
 + Locations:          University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT01894061 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 43: 
 + 
 + NCT Number:          NCT01925573 
 + 
 + Title:            Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) 
 + 
 + Acronym:            
 + 
 + Status:            Terminated 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          RECURRENT GLIOBLASTOMA|Brain Tumor 
 + 
 + Interventions:        Device: Optune(NOVOTTF-100A) 
 + 
 + Outcome Measures:       Number of Adverse Events with a grade 3 or high toxicity (Primary Measure) 
 + 
 + Sponsor/Collaborators:    University of Maryland, Baltimore|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Not Applicable 
 + 
 + Enrollment:          7 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          HP-00056719 
 + 
 + Start Date:          May 2014 
 + 
 + Primary Completion Date:   August 2019 
 + 
 + Completion Date:       August 2019 
 + 
 + First Posted:         August 19, 2013 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      November 4, 2020 
 + 
 + Locations:          Ummc Msgcc, Baltimore, Maryland, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT01925573 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 44: 
 + 
 + NCT Number:          NCT03861598 
 + 
 + Title:            Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma Multiforme|Glioblastoma 
 + 
 + Interventions:        Drug: Carvedilol 
 + 
 + Outcome Measures:       Identify the correlation between our new RT-qPCR assay for circulating tumor cells and the change in responses in patients on treatment to MRI results.|Evaluate response with the addition of carvedilol to standard chemotherapy in the second line treatment in glioblastoma multiforme|Evaluate incidents of adverse events during the time subjects are taking carvedilol with chemotherapy 
 + 
 + Sponsor/Collaborators:    West Virginia University|West Virginia Clinical and Translational Science Institute 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Early Phase 1 
 + 
 + Enrollment:          6 
 + 
 + Funded Bys:          Other 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          WVU010318 
 + 
 + Start Date:          July 19, 2019 
 + 
 + Primary Completion Date:   July 1, 2021 
 + 
 + Completion Date:       July 1, 2021 
 + 
 + First Posted:         March 4, 2019 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      August 4, 2020 
 + 
 + Locations:          WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03861598 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 45: 
 + 
 + NCT Number:          NCT04471844 
 + 
 + Title:            Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM 
 + 
 + Acronym:           EF-32 
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma Multiforme 
 + 
 + Interventions:        Device: Optune® 
 + 
 + Outcome Measures:       Overall Survival (OS)|Progression Free Survival (PFS)|1- and 2-year survival rates|Overall Radiological response (ORR)|Next progression-free survival (PFS2)|Progression-free survival at 6 (PFS6) and 12 months (PFS12)|Severity and frequency of adverse events|Pathological changes in resected GBM tumors following study treatments|Quality of Life EORTC Questionnaire|Dependence of overall survival on TTFields dose at the tumor|The NANO scale 
 + 
 + Sponsor/Collaborators:    NovoCure GmbH|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Not Applicable 
 + 
 + Enrollment:          950 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          TRIDENT EF-32 
 + 
 + Start Date:          December 8, 2020 
 + 
 + Primary Completion Date:   August 2024 
 + 
 + Completion Date:       August 2026 
 + 
 + First Posted:         July 15, 2020 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      February 21, 2021 
 + 
 + Locations:          Grandview Cancer Center, Birmingham, Alabama, United States|St. Joseph's Hospital and Medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic- Arizona, Phoenix, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center, Fullerton, California, United States|University of California at San Diego - Moores Cancer Center, La Jolla, California, United States|Memorial Care Cancer Institute - Long Beach Memorial Medical Center, Long Beach, California, United States|Norris Comprehensive Cancer Center at USC, Los Angeles, California, United States|Cedars - Sinai Medical Center, Los Angeles, California, United States|St. Joseph's Hospital, Orange, California, United States|University of California - Irvine/UCI Medical Center, Orange, California, United States|Kaiser Permanente Redwood City Medical Center, Redwood City, California, United States|Kaiser Permanente Medical Center Sacramento, Sacramento, California, United States|Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology, San Diego, California, United States|John Wayne Cancer Institute at St. John's Health Center, Santa Monica, California, United States|Stanford Cancer Institute, Stanford, California, United States|University of Colorado Cancer Center Anschutz, Aurora, Colorado, United States|HCA Research Institute - Blue Sky Neurology - Denver, Englewood, Colorado, United States|Yale University Smilow Cancer Hospital, New Haven, Connecticut, United States|Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center, New London, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Baptist Health - Jacksonville, Jacksonville, Florida, United States|Advent Health, Orlando, Florida, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States|Piedmont Healthcare Brain Tumor Center, Atlanta, Georgia, United States|The Emory Clinic - Emory Healthcare - Winship Cancer Institute, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Northwestern University, Evanston, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates, Fort Wayne, Indiana, United States|The University of Kansas Cancer Center, Overland Park, Kansas, United States|University of Louisville - James Graham Brown Cancer Center, Louisville, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|NeuroMedical Center - DelRicht Research, Baton Rouge, Louisiana, United States|LSU Health Sciences, New Orleans, Louisiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|Maine Medical Partners Neurology - Neurosurgery & Spine Associates, Scarborough, Maine, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Abbott Northwestern Hospital - Givens Brain Tumor Center, Minneapolis, Minnesota, United States|University of Minnesota Health Clinics and Surgery Center, Minneapolis, Minnesota, United States|Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|JFK Medical Center - JFK Brain Tumor Center, Edison, New Jersey, United States|Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States|Northwell Health System Brain Tumor Center, Lake Success, New York, United States|NYU Langone - Laura & Issac Perimutter Cancer Center, New York, New York, United States|Mount Sinai - Icahn School of Medicine, New York, New York, United States|New York Presbyterian - Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Forsyth Medical Center-Novant Health, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University - Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Case Western - University Hospitals Case Medical Center, Cleveland, Ohio, United States|The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital, Columbus, Ohio, United States|Providence St Vincent Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Geisinger Health System, Danville, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System - Center for Neuro-Oncology - Hillman Cancer Institute, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|MUSC Radiation Oncology Brain & Spine Tumor Program, Charleston, South Carolina, United States|West Cancer Center - Germantown, Germantown, Tennessee, United States|SCRI - Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology Midtown - Austin Brain Tumor Center, Austin, Texas, United States|Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center, Dallas, Texas, United States|John Peter Smith Health Network - JPS Cancer Center, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences, Houston, Texas, United States|San Antonio Cancer Institute, San Antonio, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|The University of Vermont Medical Center - University of Vermont Cancer Center, Burlington, Vermont, United States|Massey Cancer Center - VCU Medical Center, Richmond, Virginia, United States|UW Medical Center - Alvord Brain Tumor Center, Seattle, Washington, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, United States|Innsbruck State Hospital, Innsbruck, Austria|Kepler University Hospital, Linz, Austria|University Hospital Salzburg, Salzburg, Austria|Hospital Erasme, Brussels, Belgium|CHU de Liege - du Sart Tilman, Liège, Belgium|BC Cancer Agency Vancouver Centre, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM Centre de Recherche, Montréal, Quebec, Canada|Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita, Sherbrooke, Quebec, Canada|Masaryk Memorial Cancer Institute, Brno, Czechia|University Hospital Plzeñ, Pilsen, Czechia|Na Homolce Hospital, Prague, Czechia|Hospital CHU Nice, Nice, France|Hopital de la Pitie Salpetriere, Paris, France|Institut de Cancerologie de l'Ouest, Saint Herblain, France|Institut Universitaire du Cancer de Toulouse, Toulouse, France|Institut Gusatve Roussy, Villejuif, France|University Hospital Berlin, Berlin, Germany|University Hospital Essen, Essen, Germany|University Hospital Tübingen, Tübingen, Germany|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petah Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|CHUV - Centre Hospitalier Universitaire Vaudois, Department of Clinical Neurosciences and Oncology, Lausanne, Switzerland|University Hospital Zurich, Zürich, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT04471844 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 46: 
 + 
 + NCT Number:          NCT02343549 
 + 
 + Title:            A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM) 
 + 
 + Acronym:            
 + 
 + Status:            Terminated 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Cancer of Brain and Nervous System 
 + 
 + Interventions:        Device: bevacizumab, NovoTTF100A, temozolomide 
 + 
 + Outcome Measures:       Survival at 12 months 
 + 
 + Sponsor/Collaborators:    Ashley Love Sumrall|NovoCure Ltd.|Atrium Health 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          13 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          LCI-NEU-NOV-001|00010270 
 + 
 + Start Date:          January 2015 
 + 
 + Primary Completion Date:   July 11, 2020 
 + 
 + Completion Date:       July 11, 2020 
 + 
 + First Posted:         January 22, 2015 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      February 3, 2021 
 + 
 + Locations:          Levine Cancer Institute, Charlotte, North Carolina, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT02343549 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 47: 
 + 
 + NCT Number:          NCT03488472 
 + 
 + Title:            Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain 
 + 
 + Acronym:           RAD 1704 
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Brain Metastases|Small Cell Lung Cancer 
 + 
 + Interventions:        Device: NovoTTF-200A|Radiation: Stereotactic Radiosurgery (SRS) 
 + 
 + Outcome Measures:       Rate of Distant Metastases|Overall Survival|Local Recurrence|Distant CNS Progression 
 + 
 + Sponsor/Collaborators:    Drexell Hunter Boggs|NovoCure Ltd.|University of Alabama at Birmingham 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years to 99 Years   (Adult, Older Adult) 
 + 
 + Phases:            Not Applicable 
 + 
 + Enrollment:          20 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          IRB-300001201 
 + 
 + Start Date:          August 9, 2019 
 + 
 + Primary Completion Date:   April 2022 
 + 
 + Completion Date:       April 2022 
 + 
 + First Posted:         April 5, 2018 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      September 17, 2020 
 + 
 + Locations:          University of Alabama at Birmingham (UAB), Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03488472 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 48: 
 + 
 + NCT Number:          NCT03642080 
 + 
 + Title:            MRI Predictors of Response to Tumor Treating Fields 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma Multiforme 
 + 
 + Interventions:         
 + 
 + Outcome Measures:       Progression of disease 
 + 
 + Sponsor/Collaborators:    New York Presbyterian Brooklyn Methodist Hospital 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:             
 + 
 + Enrollment:          48 
 + 
 + Funded Bys:          Other 
 + 
 + Study Type:          Observational 
 + 
 + Study Designs:        Observational Model: Case-Only|Time Perspective: Prospective 
 + 
 + Other IDs:          1137708 
 + 
 + Start Date:          December 1, 2018 
 + 
 + Primary Completion Date:   September 30, 2021 
 + 
 + Completion Date:       December 31, 2023 
 + 
 + First Posted:         August 22, 2018 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      December 19, 2018 
 + 
 + Locations:          New York Presbyterian - Brooklyn Methodist Hospital, Brooklyn, New York, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03642080 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 49: 
 + 
 + NCT Number:          NCT03903640 
 + 
 + Title:            Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Melanoma With Brain Metastasis 
 + 
 + Interventions:        Device: Optune|Biological: Nivolumab|Biological: Ipilimumab 
 + 
 + Outcome Measures:       Intracranial progression-free survival|Overall survival|Best intracranial response rate|Best extracranial response rate|Extracranial progression-free survival|Safety of the treatment regimen as measured by number of treatment-related grade 3 or greater adverse events and discontinuations due to treatment related adverse events. 
 + 
 + Sponsor/Collaborators:    Washington University School of Medicine|NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 2 
 + 
 + Enrollment:          23 
 + 
 + Funded Bys:          Other|Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          201903162 
 + 
 + Start Date:          July 1, 2019 
 + 
 + Primary Completion Date:   January 31, 2024 
 + 
 + Completion Date:       July 31, 2027 
 + 
 + First Posted:         April 4, 2019 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      August 11, 2020 
 + 
 + Locations:          Washington University School of Medicine, Saint Louis, Missouri, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03903640 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 50: 
 + 
 + NCT Number:          NCT03203525 
 + 
 + Title:            Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer 
 + 
 + Acronym:            
 + 
 + Status:            Recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Advanced Malignant Neoplasm|Colorectal Carcinoma Metastatic in the Liver|Metastatic Malignant Neoplasm in the Liver|Refractory Malignant Neoplasm 
 + 
 + Interventions:        Biological: Bevacizumab|Drug: Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Pegylated Liposomal Doxorubicin Hydrochloride|Drug: Temsirolimus|Procedure: Tumor Treating Fields Therapy 
 + 
 + Outcome Measures:       Incidence of adverse events|Response|Biomarker analysis 
 + 
 + Sponsor/Collaborators:    M.D. Anderson Cancer Center|National Cancer Institute (NCI) 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1 
 + 
 + Enrollment:          52 
 + 
 + Funded Bys:          Other|NIH 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          2014-0357|NCI-2018-01597|P30CA016672 
 + 
 + Start Date:          June 23, 2020 
 + 
 + Primary Completion Date:   December 31, 2021 
 + 
 + Completion Date:       December 31, 2021 
 + 
 + First Posted:         June 29, 2017 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      August 12, 2020 
 + 
 + Locations:          M D Anderson Cancer Center, Houston, Texas, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT03203525 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 51: 
 + 
 + NCT Number:          NCT01756729 
 + 
 + Title:            Post-approval Study of NovoTTF-100A in Recurrent GBM Patients 
 + 
 + Acronym:            
 + 
 + Status:            Terminated 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Recurrent Glioblastoma Multiforme 
 + 
 + Interventions:        Device: NovoTTF-100A 
 + 
 + Outcome Measures:       Overall Survival|Change in neuro-cognitive function from baseline based on MMSE|Genetic profiling of tumors and correlation with response to NovoTTF-100A treatment|Adverse events severity and frequency 
 + 
 + Sponsor/Collaborators:    NovoCure Ltd. 
 + 
 + Gender:            All 
 + 
 + Age:             22 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 4 
 + 
 + Enrollment:          13 
 + 
 + Funded Bys:          Industry 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          EF-19 
 + 
 + Start Date:          December 2012 
 + 
 + Primary Completion Date:   January 2018 
 + 
 + Completion Date:       January 2018 
 + 
 + First Posted:         December 27, 2012 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      March 2, 2016 
 + 
 + Locations:          University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|Keck Medical Center of USC, Los Angeles, California, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Washington University School of Medicine, Division of Oncology, St. Louis, Missouri, United States|The Long Island Brain Tumor Center, Lake Success, New York, United States|Geisinger Health System, Danville, Pennsylvania, United States|Baylor Research Institute, Dallas, Texas, United States 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT01756729 
 + 
 + 
 + 
 +<WRAP center box 98%> 
 + 
 +Study 52: 
 + 
 + NCT Number:          NCT02903069 
 + 
 + Title:            Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer 
 + 
 + Acronym:            
 + 
 + Status:            Active, not recruiting 
 + 
 + Study Results:        No Results Available 
 + 
 + Conditions:          Glioblastoma|Malignant Glioma 
 + 
 + Interventions:        Drug: MRZ|Drug: TMZ|Radiation: RT|Device: Optune 
 + 
 + Outcome Measures:       Determine MRZ maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for both concomitant treatment (MRZ + TMZ + RT) and adjuvant treatment (MRZ + TMZ)|To assess adverse events during the adjuvant treatment|To confirm the MRZ RP2D for concomitant and adjuvant treatment in an expanded group of patients|Assess adverse events during concomitant and adjuvant treatment|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + RT|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + RT|MRZ pharmacokinetics - Maximum Serum Concentration (Cmax)|MRZ pharmacokinetics - Elimination Half-Life (t1/2)|MRZ pharmacokinetics - Area Under the Blood Concentration-Time Curve (AUC0-t, AUC0-inf)|MRZ pharmacokinetics - Clearance (CL)|MRZ pharmacokinetics - Volume of Distribution (Vd)|TMZ serum concentration|Assess neurological coordination using the Scale for the Assessment and Rating for Ataxia (SARA)|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + Optune|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + Optune 
 + 
 + Sponsor/Collaborators:    Celgene|Triphase 
 + 
 + Gender:            All 
 + 
 + Age:             18 Years and older   (Adult, Older Adult) 
 + 
 + Phases:            Phase 1 
 + 
 + Enrollment:          66 
 + 
 + Funded Bys:          Industry|Other 
 + 
 + Study Type:          Interventional 
 + 
 + Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 
 + 
 + Other IDs:          MRZ-112 
 + 
 + Start Date:          August 17, 2016 
 + 
 + Primary Completion Date:   February 26, 2021 
 + 
 + Completion Date:       February 26, 2021 
 + 
 + First Posted:         September 16, 2016 
 + 
 + Results First Posted:      
 + 
 + Last Update Posted:      March 9, 2021 
 + 
 + Locations:          University of California San Diego Medical Center, La Jolla, California, United States|UC Irvine, Orange, California, United States|John Wayne Cancer Center Outpatient Clinic, Santa Monica, California, United States|Northwestern Center For Clinical Research, Chicago, Illinois, United States|Duke Cancer Center, Durham, North Carolina, United States|Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|University of Zurich Hospital, Zurich, Switzerland 
 + 
 + Study Documents:        
 + 
 +</WRAP> 
 + 
 +URL:             https://ClinicalTrials.gov/show/NCT02903069 
 + 
 + 
 + 
clinicaltrial.1617620775.txt.gz · 最后更改: 2021/04/05 11:06 由 admin

页面工具

Donate Powered by PHP Valid HTML5 Valid CSS Driven by DokuWiki